Epidemiology of hepatocellular carcinoma: Consider the population

Journal of Clinical Gastroenterology

Volumn 47, Issue SUPPL.1, 2013, Pages

  Mittal, Sahil ^a,b   El Serag, Hashem B ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

chronic hepatitis B; chronic hepatitis C; epidemiology; hepatocellular carcinoma; prevention

Indexed keywords

AFLATOXIN; ALCOHOL; ALPHA FETOPROTEIN; GLUTATHIONE TRANSFERASE; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; LAMIVUDINE; PLACEBO; PROTEIN P53; TUMOR NECROSIS FACTOR ALPHA;

AGE DISTRIBUTION; ALCOHOL CONSUMPTION; ARGENTINA; ASPERGILLUS FLAVUS; ASPERGILLUS PARASITICUS; BRAZIL; CANCER INCIDENCE; CHINA; CHRONIC LIVER DISEASE; COFFEE; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DECOMPENSATED LIVER CIRRHOSIS; DISEASE DURATION; DISEASE SURVEILLANCE; DRINKING BEHAVIOR; ECHOGRAPHY; FAMILY HISTORY; FRANCE; GENOTYPE; GREECE; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDONESIA; INSULIN RESISTANCE; IRAN; ITALY; JAPAN; JAPANESE; LIFESTYLE; LIVER CELL CARCINOMA; LIVER FIBROSIS; MALIGNANT TRANSFORMATION; MEDICARE; META ANALYSIS; MEXICO; MIXED INFECTION; NONALCOHOLIC FATTY LIVER; NORTH KOREA; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OBSERVATIONAL STUDY; POLAND; PREGNANT WOMAN; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; RUSSIAN FEDERATION; SMOKING; SOUTH AFRICA; SOUTH KOREA; SPAIN; SWEDEN; SYSTEMATIC REVIEW; THAILAND; TOBACCO DEPENDENCE; TUMOR SUPPRESSOR GENE; TURKEY (REPUBLIC); UNITED KINGDOM; UNITED STATES; VACCINATION; VIET NAM; VIRUS LOAD;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; RISK FACTORS;

EID: 84879925475     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3182872f29     Document Type: Conference Paper

References (59)

1. GLOBOCAN. International Agency for Research on Cancer (IARC). 2002. Available at: http://www-dep.iarc.fr. Accessed 2011.
2. World Health Organization. Mortality Database. WHO Statistical Information System. 2008. Available at: http://www.who.int/whosis.
3. Bosch FX, Ribes J, Cleries R, et al. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005;9:191-211.
4. Colombo M, de Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med. 1991;325:675-680.
5. Davila JA, El-Serag HB. The rising incidence of hepatocellular carcinoma in the United States: an update. Gastroenterology. 2012;142(suppl 1):S914-S914.
6. El-Serag HB, Lau M, Eschbach K, et al. Epidemiology of hepatocellular carcinoma in Hispanics in the United States. Arch Intern Med. 2007;167:1983-1989. (Pubitemid 47606639)
7. Kanwal F, Hoang T, Kramer JR, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 2011;140:1182-1188.
8. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118:3030-3044.
9. Yang JD, Kim WR, Coelho R, et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011;9:64-70.
10. Shi J, Zhu L, Liu S, et al. A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br J Cancer. 2005;92:607-612. (Pubitemid 40395547)
11. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer. 1998;75:347-354. (Pubitemid 28100034)
12. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48:335-352.
13. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65-73. (Pubitemid 43042691)
14. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264-1273.
15. Fasani P, Sangiovanni A, De Fazio C, et al. High prevalence of multinodular hepatocellular carcinoma in patients with cirrhosis attributable to multiple risk factors. Hepatology. 1999; 29:1704-1707. (Pubitemid 29247042)
16. Stroffolini T, Andreone P, Andriulli A, et al. Gross pathologic types of hepatocellular carcinoma in Italy. Oncology. 1999;56:189-192. (Pubitemid 29161286)
17. Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology. 2002;62(suppl 1):8-17. (Pubitemid 34702014)
18. Goodgame B, Shaheen NJ, Galanko J, et al. The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias? Am J Gastroenterol. 2003;98:2535-2542. (Pubitemid 37448768)
19. Donato F, Tagger A, Gelatti U, et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol. 2002;155:323-331. (Pubitemid 34132050)
20. Lemon SM, McGivern DR. Is hepatitis C virus carcinogenic? Gastroenterology. 2012;142:1274-1278.
21. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective followup study of 384 patients. Gastroenterology. 1997;112:463-472. (Pubitemid 27078833)
22. Lok AS, Everhart JE, Wright EC, et al. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology. 2011;140:840-849.
23. Raimondi S, Bruno S, Mondelli MU, et al. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J Hepatol. 2009;50:1142-1154.
24. Welzel TM, Graubard BI, Zeuzem S, et al. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 2011;54:463-471.
25. Sanyal A, Poklepovic A, Moyneur E, et al. Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin. 2010;26:2183-2191.
26. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol. 2008;49:608-612.
27. Soderberg C, Stal P, Askling J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2010;51:595-602.
28. Arase Y, Kobayashi M, Suzuki F, et al. Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients. Hepatol Res. 2012;42:264-272.
29. Dam-Larsen S, Becker U, Franzmann MB, et al. Final results of a long-term, clinical follow-up in fatty liver patients. Scand J Gastroenterol. 2009;44:1236-1243.
30. Ratziu V, Bonyhay L, Di Martino V, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology. 2002;35:1485-1493. (Pubitemid 34966903)
31. Sanyal AJ, Banas C, Sargeant C, et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology. 2006;43:682-689.
32. Kojima H, Sakurai S, Matsumura M, et al. Cryptogenic cirrhosis in the region where obesity is not prevalent. World J Gastroenterol. 2006;12:2080-2085.
33. Yatsuji S, Hashimoto E, Tobari M, et al. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol. 2009;24:248-254.
34. Ascha MS, Hanouneh IA, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51:1972-1978.
35. Bhala N, Angulo P, van der Poorten D, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology. 2011;54:1208-1216.
36. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413-1419. (Pubitemid 29258890)
37. Adams LA, Lymp JF St, Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113-121. (Pubitemid 41002048)
38. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865-873. (Pubitemid 46489550)
39. Hashimoto E, Yatsuji S, Tobari M, et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol. 2009;44(suppl 19):89-95.
40. Kawamura Y, Arase Y, Ikeda K, et al. Large-scale long-term follow-up study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol. 2012;107:253-261.
41. Bressac B, Kew M, Wands J. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature. 1991;350:429-431. (Pubitemid 21912246)
42. Qian GS, Ross RK, Yu MC, et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev. 1994;3:3-10. (Pubitemid 24172514)
43. Hutchinson SJ, Bird SM, Goldberg DJ. Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. Clin Gastroenterol Hepatol. 2005;3:1150-1159. (Pubitemid 41565383)
44. Ikeda K, Saitoh S, Suzuki Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol. 1998;28:930-938. (Pubitemid 28275969)
45. Modi AA, Feld JJ, Park Y, et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology. 2010;51:201-209.
46. Bravi F, Bosetti C, Tavani A, et al. Coffee drinking and hepatocellular carcinoma risk: a meta-analysis. Hepatology. 2007;46:430-435. (Pubitemid 47344778)
47. Huxley R, Lee CM, Barzi F, et al. Coffee, decaffeinated coffee, and tea consumption in relation to incident type 2 diabetes mellitus: a systematic review with meta-analysis. Arch Intern Med. 2009;169:2053-2063.
48. Guo YM, Wei WY, Shen XZ. Tumour necrosis factor 308 polymorphisms and hepatocellular carcinoma risk: a metaanalysis. Hepatogastroenterology. 2010;57:926-931.
49. Qin H, Liu B, Shi T, et al. Tumour necrosis factor-alpha polymorphisms and hepatocellular carcinoma: a meta-analysis. J Int Med Res. 2010;38:760-768.
50. White DL, Li D, Nurgalieva Z, et al. Genetic variants of glutathione S-transferase as possible risk factors for hepatocellular carcinoma: a HuGE systematic review and metaanalysis. Am J Epidemiol. 2008;167:377-389. (Pubitemid 351264139)
51. Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine. 2008;26:6266-6273.
52. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521-1531.
53. Singal AG, Volk ML, Jensen D, et al. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010;8:280-288.
54. Singal AK, Singh A, Jaganmohan S, et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol. 2010;8:192-199.
55. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417-422.
56. Trevisani F, De NS, Rapaccini G, et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol. 2002;97:734-744. (Pubitemid 34245906)
57. Sherman M. Surveillance for hepatocellular carcinoma and early diagnosis. Clin Liver Dis. 2007;11:817-837. (Pubitemid 350019030)
58. Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30: 37-47.
59. El-Serag HB, Kramer JR, Chen GJ, et al. Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. Gut. 2011;60:992-997.